Could timely intervention improve long-term HS outcomes?1,2
Initiate biologic treatment before a visible tunnel appears2
Could HS be more severe than it appears?
In 1 study, nearly 45% of patients were reclassified to be more severe* after an ultrasound exam (n=38)3†
Adapted with permission from Martorell A et al. Actas Dermosifiliogr. 2015.4‡
†Based on Spanish diagnostic study of adult patients diagnosed with HS (N=143). The number of patients who may have been reclassified to a lower Hurley stage was not reported/noted by the study. The mean number of fistulas on ultrasound compared to clinical exam was not statistically significant.3
‡Images are from a 2015 Martorell study, not the same study as the data presented above.4
Consider both the seen and unseen signs of HS when assessing disease severity3,4
Refer a patient
Locate a dermatologist who specializes in the treatment of HS.
Definition
HS, hidradenitis suppurativa.
References
1. Shih T, De D, Daveluy SD, et al. Real-world considerations of candidacy for biologics in hidradenitis suppurativa. Am J Clin Dermatol. 2022;23(6):749-753.
2. van der Zee HH, Zouboulis CC, Reguiai Z, et al. The impact of lesion type on clinical response with secukinumab in patients with moderate to severe hidradenitis suppurativa: a post hoc analysis of the pooled data from SUNSHINE and SUNRISE phase 3 trials. Poster presented at: 33rd European Academy of Dermatology and Venereology (EADV) Congress; September 25-28, 2024; Amsterdam, The Netherlands. Poster P0186.
3. Martorell A, Alfageme Roldán F, Vilarassa Rull E, et al. Ultrasound as a diagnostic and management tool in hidradenitis suppurativa patients: a multicenter study. J Eur Acad Dermatol Venereol. 2019;33(11):2137-2142.
4. Martorell A, Garcia-Martínez FJ, Jiménez-Gallo D, et al. An update on hidradenitis suppurativa (part I): epidemiology, clinical aspects, and definition of disease severity. Actas Dermosifiliogr. 2015;106(9):703-715.